August 10, 2026 01:54 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘A morning I will cherish’: Raghav Chadha meets PM Modi, shares photos from ‘enriching’ meeting | Delhi Mercedes crash kills 70-year-old woman: Cop’s son behind wheel, beer bottle found | Indian-origin woman accused of ‘visa fraud’ on X: US Attorney steps in with major clarification | US Senate passes Russia sanctions bill: India can face Trump’s 100% tariff threat | Expired meat, rotten vegetables found at Bengaluru's luxury hotels, legal action begins | 'I'm ready to be humiliated': Vijay, Udhayanidhi Stalin clash in Tamil Nadu Assembly over Cauvery dispute | 'They don't need Mohan Bhagwat's certificate': Priyanka Gandhi Vadra's sharp reply to RSS chief's Gen Z remark | 'Students, Gen Z, ask me anything': Rahul Gandhi launches Instagram Q&A, responds to Jharkhand protest | PM Modi goes Gen Z, urges Indians to share 'Get Ready With Me' videos on National Handloom Day | Former Tehelka editor Tarun Tejpal sentenced to 10-year jail term in 2013 rape case as Bombay HC overturns acquittal

Sanofi Pasteur dengue vaccine approved in Costa Rica

| | Jun 24, 2016, at 05:20 am
Kolkata/Costa Rica, June 23 (IBNS): Sanofi Pasteur, Sanofi's vaccine division, announced on Thursday that the National Ministry of Health of Costa Rica has approved Sanofi Pasteur's tetravalent dengue vaccine, Dengvaxia, to protect individuals 9 to 45 years of age living in endemic areas against all four serotypes of dengue.
This approval in Costa Rica is the fourth registration of the dengue vaccine in Latin America, and the fifth in the world. Sanofi Pasteur’s dengue vaccine has already been approved in Mexico, Brazil, El Salvador and the Philippines. 
 
"Dengue is a disease that is beginning to hit us hard as a result of increased mobility and urbanization in the country. Already in 2016, we have recorded 7,711 cases of dengue at week 22 which is more than a 500% increase in incidence compared to last year,” said Jorge Martinez, Pediatrician Member of the Pediatrician Society of Costa Rica. 
 
“Approval of the dengue vaccine gives us access to critical prevention tool against dengue to curb further spread of this debilitating disease in our country.”
 
In April 2016, the Strategic Advisory Group of Experts (SAGE) on immunization to the World  Health Organization (WHO) recommended endemic countries to consider introduction of Dengvaxia as part of integrated disease prevention including vector control and community mobilization.
 
The WHO has set the objectives of reducing mortality by dengue by 50% and morbidity by 25% by 2020 in the endemic countries.
 
 “Dengue represents a growing and serious public health issue in many parts of the Americas with significant associated human and economic burden,” according to Cesar Mascareñas, Global Director of Medical Affairs for the Dengue Project, Sanofi Pasteur. “Approval of the dengue vaccine in Costa Rica will give the country’s healthcare providers access to the first clinical preventive tool against dengue, allowing them to better protect their patients against this threat.”
 
Public vaccinations against dengue began in the Philippines in April, with the goal of initiating the vaccination of 1 million fourth-grade students in highly-endemic regions of the country this year. Introduction of dengue vaccine in private and public immunization clinics in Brazil, Mexico and other countries in Central America are planned also to follow in coming months.
 
According to the WHO, dengue is currently the fastest-growing mosquito-transmitted disease in the world, causing around 400 million infections every year. Over the last 50 years, dengue has spread; initially present in a handful of countries, it is now endemic in 128, inhabited by around 4 billion people. Also, the incidence of this disease has increased 30 times in this same period.
 
Even though dengue affects people of all ages and lifestyles, the greatest number of dengue cases worldwide occurs in individuals 9 years of age and older, who represent a highly mobile and social segment of the community capable of contributing significantly to spread of the disease.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.